Alexion Pharmaceuticals: Q3 Earnings Insights

Shares of Alexion Pharmaceuticals ALXN moved higher by 6.7% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 16.13% year over year to $3.24, which beat the estimate of $2.58.

Revenue of $1,588,000,000 up by 25.73% from the same period last year, which beat the estimate of $1,420,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $11.70 and $12.00.

The upcoming fiscal year's revenue expected to be between $5,900,000,000 and $5,950,000,000.

How To Listen To The Conference Call

Date: Oct 29, 2020

Time: 09:00 AM

ET Webcast URL: https://ir.alexion.com/events-and-presentations

Recent Stock Performance

Company's 52-week high was at $128.57

52-week low: $72.67

Price action over last quarter: Up 19.52%

Company Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.